Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.43 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.43 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.43 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.43 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407566 | 0.88 | DRD1 (0.39) | CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL1407660 | 0.84 | CYP1A1 (0.46) | CYP1A2CYP3A4CYP2C19CYP2D6CYP1A1 | |
| SCHEMBL1407136 | 0.82 | MEN1 (0.44) | MEN1KMT2AMAPTCNR1CNR2 | |
| SCHEMBL1407747 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C19CYP2D6CYP1A1 | |
| SCHEMBL6276262 | 0.75 | ALDH1A1 (0.37) | CYP1A2CYP3A4CYP2C19CYP2D6CYP1A1 | |
| SCHEMBL28466675 | 0.74 | PDE4A (0.61) | CYP3A4CYP2C19CYP2C9GAAMAPK1 | |
| SCHEMBL4029988 | 0.73 | ESR1 (0.61) | CYP1A2CYP3A4CYP2C19CYP2D6CYP1A1 | |
| SCHEMBL1407678 | 0.72 | PRKAB2 (0.44) | CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL29818665 | 0.72 | PDE4A (0.59) | CYP3A4CYP2C19CYP2C9GAAMAPK1 | |
| SCHEMBL4027158 | 0.70 | ESR1 (0.45) | CYP1A2CYP3A4CYP2C19CYP2D6CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295429-A1 | 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases | Wyeth LLC (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2295429-A1 | 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7592363-B2 | Indazoles | WYETH (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060111574-A1 | Preparation and purification of 4-(indazol-3-yl) phenols | WYETH (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | NR1H2, NR1H3, CYP46A1 | CYP1A2 26/4885CYP3A4 137/4885CYP2C19 147/4885 |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | CYP1A2 2175/4885CYP3A4 2529/4885CYP2C19 1565/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | CYP1A2 2587/4885CYP3A4 2960/4885CYP2C19 2910/4885 |
| US-20060111574-A1 | Preparation and purification of 4-(indazol-3-yl) phenols | H1-10, KCNH3, H1-0 | CYP1A2 1502/4885CYP3A4 1616/4885CYP2C19 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.